Bio-Rad Laboratories, Inc.'s (BIO) robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics areas. The company's emphasis on international expansion is encouraging. Meanwhile, the persistent softness in the Biopharma segment and negative economic impacts on Bio-Rad's margin performance raise concerns. In the past ye ...

MINNEAPOLIS, Sept. 24, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its portfolio of solutions advancing neuroscience research at the upcoming annual meeting of the Society for Neuroscience (SfN) at Neuroscience 2024, taking place October 5-9, 2024, in Chicago, Illinois. At booth #1165, Bio-Techne will feature its market-leading portfolio of high-quality life science reagents, immunoassays, automated proteomic analytical instruments, and multiomics solutions. T ...

VANCOUVER, British Columbia and HOLMDEL, N.J., Sept. 23, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that its long-time customer, the province of British Columbia, has placed new orders with BIO-key. 10,000 users will be added to their existing deploy ...

MINNEAPOLIS, Sept. 18, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today issued its 2024 Corporate Sustainability Report (CSR), detailing the continued progress advancing its Environmental, Social and Governance (ESG) initiatives. Bio-Techne's CSR is organized around four key pillars: Our People, Advancing Science, Governance and Operational Integrity, and The Environment. Bio-Techne's EPIC values (Empowerment, Passion, Innovation and Collaboration) remain the backbone of our corporate cultur ...

HOLMDEL, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, today announced it has entered into a warrant inducement agreement with an existing institutional investor for the immediate exercise of certain outstanding warrants that the Company issued on ...

HOLMDEL, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication experiences, announced that one of the world's most respected government defense ministries has awarded BIO-key over $500K in new orders for BIO-key's biometric user authentication solution pursuant to a t ...

MINNEAPOLIS, Aug. 26, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 4:05 PM EDT 2024 Wells Fargo Healthcare Conference September 6, 2024 11:00 AM EDT Baird 2024 Global Healthcare Conference September 10, 2024 1:25 PM EDT A live webcast of the presentations can be accessed via the IR Calendar page o ...

HOLMDEL, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and token-less Identity-Bound Biometrics (IBB) authentication solutions, will participate at H.C. Wainwright's 26th Annual Hybrid Global Investment Conference September 9th and 10th. BIO-key's CEO Mike DePasquale will be available for virtual meetings on Monday and Tuesday, September 9th ...

文章核心观点 - 公司的Digital PCR业务增长强劲,Droplet Digital PCR平台表现出色 [5][6] - 公司的临床诊断业务持续增长,主要得益于质控和血型产品需求的增加 [7][8] - 公司财务状况稳健,现金和现金等价物充足,偿债能力强 [9] - 但生物制药业务疲软,受到宏观经济环境的不利影响 [10][11][12] - 公司面临成本压力,毛利率受到原材料价格上涨、物流成本增加和员工成本上升的影响 [13] - 公司面临激烈的竞争压力,价格竞争加剧 [14][15] 公司概况 - 公司是一家临床诊断和生命科学研究产品的制造商和全球供应商 [3] - 公司市值为89.2亿美元 [3] - 过去5年公司的收益增长率为15.6%,远高于行业3.7%的增长率 [4] - 公司的季度业绩表现良好,超出预期的概率较高 [4] 业务表现 - Digital PCR业务增长强劲,公司正在不断提高产能以满足需求 [5][6] - 临床诊断业务中的糖尿病、免疫血液学和质控业务表现良好 [7][8] - 生物制药业务受到宏观经济环境的不利影响,出现需求下降 [10][11][12] 财务状况 - 公司现金和现金等价物充足,偿债能力强 [9] - 但面临成本压力,毛利率受到不利影响 [13] 竞争环境 - 公司面临激烈的竞争压力,价格竞争加剧 [14][15]

HOLMDEL, N.J. , Aug. 15, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software featuring passwordless, phoneless and token-less Identity-Bound Biometrics (IBB) authentication solutions, announced the availability of its PortalGuard IDaaS platform in the Amazon Web Services (AWS) Marketplace enabling AWS customers around the world to seamlessly purchase and integrate PortalGuard and its IBB authenti ...